NasdaqCM:EVOK

Stock Analysis Report

Executive Summary

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases.

Risk Analysis

Earnings are forecast to decline by an average of -0.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Evoke Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVOK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.5%

EVOK

-1.7%

US Pharmaceuticals

0.06%

US Market


1 Year Return

-52.6%

EVOK

6.5%

US Pharmaceuticals

19.4%

US Market

Return vs Industry: EVOK underperformed the US Pharmaceuticals industry which returned 6.5% over the past year.

Return vs Market: EVOK underperformed the US Market which returned 19.4% over the past year.


Shareholder returns

EVOKIndustryMarket
7 Day3.5%-1.7%0.06%
30 Day-6.0%-3.2%1.1%
90 Day20.3%6.8%8.9%
1 Year-52.6%-52.6%9.2%6.5%21.9%19.4%
3 Year-53.8%-53.8%27.8%18.6%48.9%39.3%
5 Year-73.1%-73.1%22.9%10.4%71.9%53.1%

Price Volatility Vs. Market

How volatile is Evoke Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evoke Pharma undervalued compared to its fair value and its price relative to the market?

6.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVOK is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: EVOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVOK is overvalued based on its PB Ratio (6.9x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Evoke Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if EVOK's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if EVOK's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evoke Pharma performed over the past 5 years?

11.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVOK is currently unprofitable.

Growing Profit Margin: EVOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 11.7% per year.

Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).


Return on Equity

High ROE: EVOK has a negative Return on Equity (-144.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Evoke Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVOK's short term assets ($7.3M) exceed its short term liabilities ($2.2M).

Long Term Liabilities: EVOK has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVOK is debt free.

Reducing Debt: EVOK has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.


Balance Sheet

Inventory Level: EVOK has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if EVOK's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EVOK has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -0% each year.


Next Steps

Dividend

What is Evoke Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.7yrs

Average board tenure


CEO

Dave Gonyer (55yo)

12.9yrs

Tenure

US$1,144,313

Compensation

Mr. David A. Gonyer, also known as Dave, R.Ph., is a Co-Founder of Evoke Pharma, Inc. and has been its Chief Executive Officer and President since March 2007. Mr. Gonyer held senior management positions bo ...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD1.14M) is above average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
David Gonyer
Co-Founder12.9yrsUS$1.14m1.32% $472.9k
Ann Rhoads
Independent Director6.7yrsUS$111.43kno data
Kenneth Widder
Independent Director12.7yrsUS$100.05kno data
Todd Brady
Independent Director12.7yrsUS$100.55k0.017% $5.9k
Cam Garner
Chairman of the Board12.7yrsUS$113.18k1.38% $496.7k
Malcolm Hill
Independent Director12.7yrsUS$91.92k0.079% $28.5k

12.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: EVOK's board of directors are seasoned and experienced ( 12.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.


Top Shareholders

Company Information

Evoke Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evoke Pharma, Inc.
  • Ticker: EVOK
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$35.863m
  • Shares outstanding: 24.23m
  • Website: https://www.evokepharma.com

Number of Employees


Location

  • Evoke Pharma, Inc.
  • 420 Stevens Avenue
  • Suite 370
  • Solana Beach
  • California
  • 92075
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVOKNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2013
EV0DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 01:55
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.